Advertisement

Pharmaka zur Behandlung und Prophylaxe von Infektionskrankheiten

  • E. Oberdisse
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Der Begriff der Chemotherapie geht auf Paul Ehrlich zurück, der sie als eine spezifische, gegen Krankheitserreger gerichtete Therapie den körpereigenen Abwehrkräften gegenüberstellte. Seine „Chemotherapia specifica“ist die Anwendung von Substanzen, die für Krankheitserreger tödlich sind und in den verwendeten Dosen den Warmblüter nicht schädigen. Diese Forderung beinhaltet die Feststellung der therapeutischen Breite eines Pharmakons, die durch das Verhältnis von Dosis tolerata zur Dosis curativa beschrieben wird und in dieser Definition noch heute gültig ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allen A (1992) The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529–542PubMedGoogle Scholar
  2. Alrabiah FA, Sacks SL (1996) New antiherpesvirus agents: Their targets and therapeutic potential. Drugs 52:17–32PubMedCrossRefGoogle Scholar
  3. Andus T, Palitzsch K-D, Gross V, Schölmerich J (1993) Metabolische und endokrine Funktionen der Zytokine, Dtsch Med Wochenschr 118, 306–313PubMedCrossRefGoogle Scholar
  4. Bäder G (1992) Molecular-Modelling-Untersuchung am penicillinbindenden Protein 5 von Escherichia coli K 12, Inaug-Diss, Fach Pharmazie, Fr Univ BerlinGoogle Scholar
  5. Balfour JA, Bryson HM, Brogden RN (1996) Imipenem/Cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 51:99–136PubMedCrossRefGoogle Scholar
  6. Barclay ML, Begg EJ, Hickling KG (1994) What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 27:32–48PubMedCrossRefGoogle Scholar
  7. Barradell LB, Fitton A (1995) Artesunate: A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 50:714–741PubMedCrossRefGoogle Scholar
  8. Blanchard JS (1996) Molecular mechanisms of drug resistance in mycobacterium tuberculosis. Annu Rev Biochem 65:215–239PubMedCrossRefGoogle Scholar
  9. Brogden RN, Fitton A (1994) Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drug 47:983–1009CrossRefGoogle Scholar
  10. Brogden RN, Peters DH (1994) Teicoplanin: A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:823–854PubMedCrossRefGoogle Scholar
  11. Bryson HM, Brogden RN (1994) Piperacillin/Tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 47:506–535PubMedCrossRefGoogle Scholar
  12. Chopra I, Hawkey PM, Hinton M (1992) Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 29: 245–277PubMedCrossRefGoogle Scholar
  13. Como JA, Dismukes WE (1994) Oral azole drugs as systemic antifungal therapy, N Engl J Med 330: 263–272PubMedCrossRefGoogle Scholar
  14. Crumpacker CS (1989) Molecular targets of antiviral therapy. N Engl J Med 321:163–172PubMedCrossRefGoogle Scholar
  15. Davis R, Bryson HM (1994) Levofloxacin: A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677–700PubMedCrossRefGoogle Scholar
  16. Davis R, Markham A, Balfour JA (1996) Ciprofloxacin: An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51:1019–1074PubMedCrossRefGoogle Scholar
  17. De Isabella P, Capranico G, Zunino F (1991) The role of topoisomerase II in drug resistance. Life Sci 48:2195–2205PubMedCrossRefGoogle Scholar
  18. De Kruijff B, Demel RA (1974) Polyene antibiotic-sterol interactions in membranes of acholeplasma laidlawii cells and lecithin liposomes. III. Molecular structures of the polyene antibiotic-cholesterol complexes. Biochim Biophys Acta 339:57–70PubMedCrossRefGoogle Scholar
  19. Drews J (1979) Grundlagen der Chemotherapie. Springer, WienCrossRefGoogle Scholar
  20. Dunn CJ, Barradell LB (1996) Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 51:483–505PubMedCrossRefGoogle Scholar
  21. Erickson JW, Burt SK (1996) Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 36:545–571PubMedCrossRefGoogle Scholar
  22. Friedel HA, Campoli-Richards DM, Goa KL (1989) Sultamicillin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 37:491–522PubMedCrossRefGoogle Scholar
  23. Fulton B (1995) Trimetrexate: A review of its pharmacodynamic and pharmacokinetic properties and therpeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs 49:563–576PubMedCrossRefGoogle Scholar
  24. Ghuysen J-M (1991) Serine β-lactamases and penicillin-bindung proteins. Annu Rev Microbiol 45:37–67PubMedCrossRefGoogle Scholar
  25. Gillum JG, Israel DS, Polk RE (1993) Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 25:450–482PubMedCrossRefGoogle Scholar
  26. Goa KL, Barradell LB (1995) Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690PubMedCrossRefGoogle Scholar
  27. Gräfe, U (1992) Biochemie der Antibiotika: Struktur, Biosynthese, Wirkmechanismus. Spektrum, Heidelberg Berlin New YorkGoogle Scholar
  28. Guay DRP (1996) Macrolide antibiotics in paediatric infectious diseases. Drugs 51:515–536PubMedCrossRefGoogle Scholar
  29. Guerrant RL, Bobak DA (1991) Bacterial and protozoal gastroenteritis. N Engl J Med 325:327–340PubMedCrossRefGoogle Scholar
  30. Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview 1. J Amer Acad Dermatol 30:677–698CrossRefGoogle Scholar
  31. Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: An overview 2. J Amer Acad Dermatol 30:911–933CrossRefGoogle Scholar
  32. Haria M, Benfield P (1995) Interferon-α-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50:873–896PubMedCrossRefGoogle Scholar
  33. Haria M, Bryson HM (1995) Amorolfine: A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49:103–120PubMedCrossRefGoogle Scholar
  34. Haria M, Bryson HM, Goa KL (1996) Itraconazole: A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585–620PubMedCrossRefGoogle Scholar
  35. Heisig P (1994) Mechanismen bakterieller Resistenz gegen Antibiotika. Arzneimitteltherapie 12:203–218Google Scholar
  36. Hirsch MS, D’Aquila RT (1993) Therapy for human immunodeficiency virus infection. N Engl J Med 328:1686–1695PubMedCrossRefGoogle Scholar
  37. Höffken K, Schmidt CG, Mertelsmann RH, Herrmann F (1990) Modulation physiologischer Regulationsmechanismen durch Zytokine. Dtsch Arztebl 87:62410–62416Google Scholar
  38. Hooper DC, Wolfson JS (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324:384–394PubMedCrossRefGoogle Scholar
  39. Iseman MD (1993) Treatment of multidrug-resistant tuberculosis. N Engl J Med 239:784–791Google Scholar
  40. Jacoby GA, Archer GL (1991) New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 324:601–612PubMedCrossRefGoogle Scholar
  41. Jacoby GA, Medeiros AA (1991) More extended-spectrum β-lactamases. Antimicrob Agents Chemother 35:1697–1704PubMedGoogle Scholar
  42. Jaeger A, Sauder P, Kopferschmitt J, Flesch F (1987) Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol 2:242–273Google Scholar
  43. Katz M (1986) Current concepts in the treatment of helminthic infections, Drugs 32:358–371PubMedCrossRefGoogle Scholar
  44. Kirchhoff LV (1993) American Trypanosomiasis (Chargas disease) — a tropical disease now in the United States. N Engl J Med 329:639–644PubMedCrossRefGoogle Scholar
  45. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23: 328–364PubMedCrossRefGoogle Scholar
  46. Lea AP, Bryson HM (1996) Cidofovir. Drugs 52:225–230CrossRefGoogle Scholar
  47. Lipman B, Neu HC (1988) Imipenem: A new carbapenem antibiotic. Med Clin North Amer 72:567–79Google Scholar
  48. Mandell WF, Neu HC (1988) Parasitic infections: Therapeutic considerations. Med Clin North Am 72:669–90PubMedGoogle Scholar
  49. Marra F, Partovi N, Jewesson P (1996) Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs 52:344–370PubMedCrossRefGoogle Scholar
  50. McCormack JP, Jewesson PJ (1992) A critical reevaluation of the „therapeutic range“of aminoglycosides. Clin Infect Dis 14:320–339PubMedCrossRefGoogle Scholar
  51. Nathwani D, Wood MJ (1993) Penicillins: A current review of their clinical pharmacology and therapeutic use. Drugs 45:866–894PubMedCrossRefGoogle Scholar
  52. Neu HC (1987) General concepts on the chemotherapy of infectious diseases. Med Clin North Am 71:1051–1064PubMedGoogle Scholar
  53. Neu HC (1988) Aztreonam: The first monobactam. Med Clin North Am 72:555–566PubMedGoogle Scholar
  54. Neu HC (1992) Quinolone antimicrobial agents. Annu Rev Med 43:456–486CrossRefGoogle Scholar
  55. Paap CM, Nahata MC (1990) Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 19:280–318PubMedCrossRefGoogle Scholar
  56. Panisko DM, Keystone JS (1990) Treatment of malaria — 1990. Drugs 39:160–189PubMedCrossRefGoogle Scholar
  57. Patel SS, Spencer CM (1996) Enoxacin: A reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. Drugs 51:137–160PubMedCrossRefGoogle Scholar
  58. Periti P, Mazzei T, Mini E, Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106–131PubMedCrossRefGoogle Scholar
  59. Perry CM, Brogden RN (1996) Cefuroxime Axetil: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 52:125–158PubMedCrossRefGoogle Scholar
  60. Peters W (1990) The prevention of antimalarial drug resistance. Pharmacol Ther 47:499–508PubMedCrossRefGoogle Scholar
  61. Phillips I, Shannon K (1989) Class I β-Lactamases: Induction and derepression. Drugs 37:402–407PubMedCrossRefGoogle Scholar
  62. Pratt WB, Fekety R (1986) The antimicrobial drugs. Oxford Univ Press, New York OxfordGoogle Scholar
  63. Rains CP, Bryson HM, Peters DH (1995) Ceftazidime: An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49:577–617PubMedCrossRefGoogle Scholar
  64. Reimann IW, Kemmler H, Boulat O, Voigt B-U (1991) Chloroquin, Teil I: Pharmakokinetik und Wirkungsmechanismen. Med Monatsschr Pharm 9:206–214Google Scholar
  65. Rybak MJ, McGrath BJ (1996) Combination antimicrobial therapy for bacterial infections. Drugs 52:390–405PubMedCrossRefGoogle Scholar
  66. Ryley JF (ed) (1990) Chemotherapy of fungal diseases, In: Handbook of experimental Pharmacology, vol 96. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  67. Sanders CC (1992) β-lactamases of gram-negative bacteria: New challenges for new drugs. Clin Infec Dis 14:1089–1099CrossRefGoogle Scholar
  68. Schaberg T, Lode H (1990) Therapie der Tuberkulose. Dtsch Med Wochenschr 115:1799–1802PubMedCrossRefGoogle Scholar
  69. Seas C, DuPont HL, Valdez LM, Gotuzzo E (1996) Practical guidelines for the treatment of cholera. Drugs 51:966–973PubMedCrossRefGoogle Scholar
  70. Simon C, Stille W (1997) Antibiotika-Therapie in Klinik und Praxis, 9. Aufl. Schattauer, Stuttgart New YorkGoogle Scholar
  71. Slater AFG (1993) Chloroquine: Mechanism of drug action and resistance in plasmodium falciparum. Pharmacol Ther 57:203–235PubMedCrossRefGoogle Scholar
  72. Spencer CM, Goa KL (1995) Atovaquone: A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 50:176–196PubMedCrossRefGoogle Scholar
  73. St Peter WL, Redic-Kill KA, Halstenson CE (1992) Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 22:169–210PubMedCrossRefGoogle Scholar
  74. Strominger JL, Izaki K, Matsuhashi M, Tipper DJ (1976) Peptidoglycan transpeptidase and D-alanine carboxypeptidase: penicillin-sensitive enzymatic reactions. Fed Proc 26:9–22Google Scholar
  75. Stupp H, Rauch S, Sous H et al (1966) Untersuchungen über die Ursache der spezifisch ototoxischen Wirkung der basischen Streptomyces-Antibiotika unter besonderer Berücksichtigung des Kanamycins. Acta Otolaryng 61:436–444PubMedCrossRefGoogle Scholar
  76. Sykes RB, Mathew M (1976) The β-lactamases of gram-negative bacteria and their role in resistance to β-lactam antibiotics. J Antimicrob Chemo Ther 2:115–157CrossRefGoogle Scholar
  77. Tompkins LS (1992) The use of molecular methods in infectious diseases. N Engl J Med 327:1290–1297PubMedCrossRefGoogle Scholar
  78. Vanden Bossche H, Thienpont D, Janssens PG (eds) (1985) Chemotherapy of gastrointestinal helminths, In: Handbook of experimental Pharmacology, vol 77. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  79. von Rosenstiel N, Adam D (1994) Quinolone antibacterials: An update of their pharmacology and therapeutic use. Drugs 47:872–901CrossRefGoogle Scholar
  80. Wagstaff AJ, Faulds D, Goa KL (1994) Aciclovir: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153–205PubMedCrossRefGoogle Scholar
  81. Wallhäusser KH (1995) Praxis der Sterilisation, Desinfektion, Konservierung, 5.Aufl. Thieme, StuttgartGoogle Scholar
  82. Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of african trypanosomiasis. Annu Rev Pharmacol Toxicol 35:93–127PubMedCrossRefGoogle Scholar
  83. Westphal J-F, Brogard J-M (1993) Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet 24:46–58PubMedCrossRefGoogle Scholar
  84. Williams JD (1987) The cephalosporin antibiotics. Drugs 34 [Suppl 2]:1–285Google Scholar
  85. Wiseman LR, Balfour JA (1994) Ceftibuten: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 47:784–808PubMedCrossRefGoogle Scholar
  86. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM (1995) Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73–101PubMedCrossRefGoogle Scholar
  87. Wood AJJ (1996) Antimicrobial-drug resistance. New Engl J Med 335:1445–1453CrossRefGoogle Scholar
  88. Wyler DJ (1993) Malaria chemoprophylaxis for the traveler. N Engl J Med 239:31–37Google Scholar
  89. Wyler DJ (1993) Malaria: Overview and update. Clin Infect Dis 16:449–458PubMedCrossRefGoogle Scholar
  90. Young RA, Gonzalez JP, Sorkin EM (1989) Roxithromycin: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37:8–41PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Oberdisse

There are no affiliations available

Personalised recommendations